# Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

> **NCT06848569** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 73 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Sintilimab in combination with AVD chemotherapy

## Key facts

- **NCT ID:** NCT06848569
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-23
- **Primary completion:** 2027-10-23
- **Final completion:** 2031-10-23
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848569, "Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06848569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*